COMMUNIQUÉS West-GlobeNewswire

Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
26/10/2026
RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 [...]
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
26/10/2026
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company [...]
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
26/10/2026
Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker has completed its acquisition of ZuriMED, adding the FiberLocker System to its Sports Medicine portfolio The acquisition adds a commercialized rotator cuff [...]
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
26/10/2026
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 Built on the proven sensing technology behind [...]
Major shareholder announcement
26/10/2026
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis. As of October 21, 2026, BlackRock, Inc.’s [...]
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
26/10/2026
Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade). The objective response rate (ORR) based on Response Assessment in Neuro-Oncology [...]
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
26/10/2026
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in [...]
Weight Watchers Schedules Third Quarter 2026 Earnings Conference Call
26/10/2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”) will release its results for the third quarter 2026 ended September 30, 2026, before market open on [...]
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
26/10/2026
Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancer Updated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability VANCOUVER, Washington, Oct. 26 [...]
SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences
26/10/2026
FORT LAUDERDALE, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) -- via IBN – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII) , a developer of innovative surgical robotic technologies [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
26/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
26/10/2026
Peer-Reviewed Scientific Reports Data & Academic Collaboration Show Potent Anti-Tumor Activity, EMT Reversal, & Sequential Chemo-Sensitization; Phase 1b First-In-Human Study Planned for Q1 2027 MELBOURNE, [...]
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
26/10/2026
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p [...]
Ambros Therapeutics Announces Planned Interim Analysis of Phase 3 Clinical Trial Following FDA Feedback
26/10/2026
Company plans group sequential design with an interim analysis that could allow the trial to stop early Neridronate has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations SAN DIEGO, Oct. 26, [...]
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
26/10/2026
MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and IL-15 signalling Long [...]
Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
26/10/2026
Durability of faridoxorubicin (AVA6000) activity results from the continued release of doxorubicin by fibroblast activation protein (FAP) demonstrated beyond 10 cycles of therapy FAPI-PET imaging data indicate prolonged [...]
Imprivata Recognized for the First Time in the Gartner® Magic Quadrant™ for Privileged Access Management
26/10/2026
Imprivata combines privileged, agentic AI, and third-party access management into a single comprehensive platform to help organizations reduce risk, meet regulatory compliance requirements, and improve operational [...]
More Than 1 in 10 People Receive Medically Actionable Genetic Results Through 23andMe, Analysis of Nearly 6 Million Participants Finds
26/10/2026
Early findings presented at ASHG 2026 indicate nearly all people choose to learn their genetic health risks when given the option PALO ALTO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- New research from 23andMe Research [...]
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
26/10/2026
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum